Documentation
Description:
UNIRAD: Randomised, double-blind, multicentre phase III trial evaluating
the safety and benefit of adding everolimus to adjuvant hormone
therapy in women with high risk of relapse, ER+ and HER2-
primary breast cancer who remain free of disease
Collection of UK samples and data across the following diseases: Malignant tumour of breast
Coverage
Spatial:
United Kingdom
Follow Up:
1 - 10 Years
Provenance
Origin
Purposes:
Trial
Temporal
Accrual Periodicity:
Static
Start Date:
23 May 2022
Time Lag:
Not applicable
Accessibility
Access
Access Rights:
Please contact the publisher using Contact Point details provided
Access Request Cost:
Not specified
Delivery Lead Time:
Other
Jurisdictions:
UK
Data Controller:
The Institute of Cancer Research
Data Processor:
The Institute of Cancer Research
Format and Standards
Vocabulary Encoding Schemes:
LOCAL
Conforms To:
LOCAL
Languages:
en
Formats:
In Progress